EA201892672A1 - Лечение боли - Google Patents

Лечение боли

Info

Publication number
EA201892672A1
EA201892672A1 EA201892672A EA201892672A EA201892672A1 EA 201892672 A1 EA201892672 A1 EA 201892672A1 EA 201892672 A EA201892672 A EA 201892672A EA 201892672 A EA201892672 A EA 201892672A EA 201892672 A1 EA201892672 A1 EA 201892672A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pain treatment
compounds
pain
treatment
par
Prior art date
Application number
EA201892672A
Other languages
English (en)
Russian (ru)
Inventor
Найджел Баннет
Original Assignee
Такеда Фармасьютикал Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016901912A external-priority patent/AU2016901912A0/en
Application filed by Такеда Фармасьютикал Компани Лимитед filed Critical Такеда Фармасьютикал Компани Лимитед
Publication of EA201892672A1 publication Critical patent/EA201892672A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA201892672A 2016-05-20 2017-05-19 Лечение боли EA201892672A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2016901912A AU2016901912A0 (en) 2016-05-20 Treatment of Pain
PCT/AU2017/050469 WO2017197463A1 (en) 2016-05-20 2017-05-19 Treatment of pain

Publications (1)

Publication Number Publication Date
EA201892672A1 true EA201892672A1 (ru) 2019-04-30

Family

ID=60324618

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892672A EA201892672A1 (ru) 2016-05-20 2017-05-19 Лечение боли

Country Status (10)

Country Link
US (1) US20190298743A1 (enExample)
EP (1) EP3458062A4 (enExample)
JP (3) JP2019516734A (enExample)
CN (1) CN109152777A (enExample)
AU (3) AU2017268039A1 (enExample)
CA (1) CA3024719A1 (enExample)
EA (1) EA201892672A1 (enExample)
MX (2) MX395658B (enExample)
NZ (2) NZ788380A (enExample)
WO (1) WO2017197463A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3086458A1 (en) * 2017-12-20 2019-06-27 Takeda Pharmaceutical Company Limited Inhibitors of protease activated receptor-2
US20240066027A1 (en) 2020-12-03 2024-02-29 Domain Therapeutics Novel par-2 inhibitors
WO2023233033A1 (en) 2022-06-03 2023-12-07 Domain Therapeutics Novel par-2 inhibitors
WO2025172573A1 (en) 2024-02-16 2025-08-21 Domain Therapeutics Combinations of par2 inhibitors and immune checkpoint inhibitors for the treatment of cancer
WO2025191185A1 (en) 2024-03-15 2025-09-18 Domain Therapeutics Azine-based compounds as par-2 inhibitors and therapeutic uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106998A0 (en) * 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
US7541156B1 (en) * 2000-03-01 2009-06-02 Pasricha Pankaj J Method of identifying antinociceptive compounds using protease activated receptor-2
GB2426517A (en) * 2003-11-21 2006-11-29 Univ Newcastle Res Ass Methods and agents for inhibiting dynamin-dependent endocytosis
CN1938013A (zh) * 2003-11-21 2007-03-28 纽卡斯尔大学研究协会有限公司 抑制发动蛋白依赖性的细胞内摄作用的方法和药剂
CA2562266A1 (en) * 2004-04-08 2005-10-20 Jadolabs Gmbh Tripartite conjugates containing a structure interacting with cell membrane rafts and their use
JP4896870B2 (ja) * 2004-04-08 2012-03-14 ヤード・テヒノロギース・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞膜ラフトと相互作用する構造を含む三者複合体およびその使用
WO2009034464A2 (en) * 2007-09-12 2009-03-19 Newcastle Innovation Limited Indole related compounds with physiological activity
AR070911A1 (es) * 2008-03-19 2010-05-12 Regeneron Pharma Uso de antagonistas del receptor par2 activado con proteasa
WO2013010218A1 (en) * 2011-07-15 2013-01-24 Freie Universität Berlin Inhibition of clathrin
TW201602109A (zh) * 2013-09-25 2016-01-16 維泰克斯製藥公司 作為par-2訊息傳遞路徑之抑制劑之咪唑并嗒
CN115531553A (zh) * 2015-12-22 2022-12-30 武田药品工业株式会社 内体g蛋白-偶联的受体的三部分调节剂
AT518095B1 (de) * 2015-12-30 2018-01-15 Univ Wien Tech Verfahren zur Herstellung von ionischen Flüssigkeiten auf Basis des Bistriflimid-Anions
CA3086458A1 (en) * 2017-12-20 2019-06-27 Takeda Pharmaceutical Company Limited Inhibitors of protease activated receptor-2

Also Published As

Publication number Publication date
MX395658B (es) 2025-03-26
JP2024073450A (ja) 2024-05-29
EP3458062A1 (en) 2019-03-27
AU2023201732A1 (en) 2023-04-20
CA3024719A1 (en) 2017-11-23
JP2022061998A (ja) 2022-04-19
JP2019516734A (ja) 2019-06-20
AU2025202933A1 (en) 2025-05-15
JP7441246B2 (ja) 2024-02-29
NZ748579A (en) 2025-07-25
CN109152777A (zh) 2019-01-04
AU2017268039A1 (en) 2018-12-06
EP3458062A4 (en) 2020-01-15
MX2022011564A (es) 2023-06-15
MX2018014135A (es) 2019-06-17
NZ788380A (en) 2025-07-25
WO2017197463A1 (en) 2017-11-23
US20190298743A1 (en) 2019-10-03

Similar Documents

Publication Publication Date Title
EA201890204A1 (ru) Антибактериальные соединения
EA201990043A1 (ru) Антибактериальные соединения
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201890530A1 (ru) Конъюгаты антитела к dll3 и лекарственного средства и способы их применения
EA201790413A1 (ru) Антитела против tigit
MX378273B (es) Compuestos activos hacia bromodominios.
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
EA201991997A1 (ru) Комбинированная терапия
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201591925A1 (ru) Терапевтические композиции и их применение
EA202191301A1 (ru) СОСТАВ ТАБЛЕТОК 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
EA201792157A1 (ru) Имидазопиразиноны в качестве ингибиторов pde1
EA201890810A1 (ru) Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
EA201892672A1 (ru) Лечение боли
MX379359B (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
EA201790773A1 (ru) Композиции и способы для ингибирования биологической активности растворимых биомолекул
EA201692032A1 (ru) Антибактериальные соединения
EA202090270A1 (ru) Новые замещенные производные ксантина
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA201792123A1 (ru) Лечение боли
MX375318B (es) Formas de dosificación y usos terapéuticos de l-4-cloro quinurenina..